IM Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
4
IM Therapeutics General Information
Description
Developer of a biotechnology platform designed to build drug molecules for specific blockade of autoimmune disease-associated antibodies. The company's platform screens compounds for optimal docking within human leukocyte antigens, together with rational drug design and bioassays to build targeted therapeutic candidates, enabling patients and health professionals to detect early signs across autoimmune diseases.
Contact Information
Website
www.imtherapeutics.comCorporate Office
- 299 Washington Street
- Suite A
- Woburn, MA 01801
- United States
Corporate Office
- 299 Washington Street
- Suite A
- Woburn, MA 01801
- United States
IM Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Later Stage VC (Series A) | 30-Oct-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 09-Oct-2019 | Completed | Startup | |||
| 3. Angel (individual) | 03-Aug-2016 | Completed | Startup | |||
| 2. Angel (individual) | 30-Jun-2015 | $500K | $500K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
IM Therapeutics Comparisons
Industry
Financing
Details
IM Therapeutics Competitors (55)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Second Genome | Formerly VC-backed | Brisbane, CA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| AnTolRx | Venture Capital-Backed | Cambridge, MA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Xenikos | Venture Capital-Backed | Nijmegen, Netherlands |
IM Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IM Therapeutics Patents
IM Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220194893-A1 | Methods for producing d-alpha-methyldopa | Active | 23-Dec-2020 | ||
| EP-4267123-A1 | Methods for producing d-?-methyldopa | Pending | 23-Dec-2020 | ||
| US-11702383-B2 | Methods for producing d-α-methyldopa | Active | 23-Dec-2020 | ||
| US-20220204471-A1 | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 | Active | 22-Dec-2020 | ||
| US-11945790-B2 | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 | Active | 22-Dec-2020 | C07D317/60 |
IM Therapeutics Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Nandan Padukone Ph.D | Chief Executive Officer & Board Member | |
| Aaron Michels MD | Co-Founder & Chief Scientific Officer | |
| Peter Gottlieb MD | Co-Founder, Chief Medical Officer & Board Member | |
| Thomas Shea | Chief Financial Officer & Chief Operating Officer | |
| Jonathan Rigby | Board Member & Independent Director |
IM Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aaron Michels MD | IM Therapeutics | Co-Founder & Chief Scientific Officer | |
| Ed Orr | Self | Board Member | |
| Jason Dinges Ph.D | Self | Board Member | |
| Jonathan Rigby | Self | Board Member & Independent Director | |
| Nandan Padukone Ph.D | IM Therapeutics | Chief Executive Officer & Board Member |
IM Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IM Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CU Healthcare Innovation Fund | Corporate Venture Capital | Minority | ||
| Morningside Group | Venture Capital | Minority | ||
| T1D Fund | Venture Capital | Minority | ||
| C2I Accelerator | Accelerator/Incubator |
IM Therapeutics FAQs
-
When was IM Therapeutics founded?
IM Therapeutics was founded in 2015.
-
Who is the founder of IM Therapeutics?
Aaron Michels MD, Sunanda Babu Ph.D, Peter Gottlieb MD, and Steve Orndorff Ph.D are the founders of IM Therapeutics.
-
Who is the CEO of IM Therapeutics?
Nandan Padukone Ph.D is the CEO of IM Therapeutics.
-
Where is IM Therapeutics headquartered?
IM Therapeutics is headquartered in Woburn, MA.
-
What is the size of IM Therapeutics?
IM Therapeutics has 3 total employees.
-
What industry is IM Therapeutics in?
IM Therapeutics’s primary industry is Drug Discovery.
-
Is IM Therapeutics a private or public company?
IM Therapeutics is a Private company.
-
What is IM Therapeutics’s current revenue?
The current revenue for IM Therapeutics is .
-
How much funding has IM Therapeutics raised over time?
IM Therapeutics has raised $17.9M.
-
Who are IM Therapeutics’s investors?
CU Healthcare Innovation Fund, Morningside Group, T1D Fund, and C2I Accelerator have invested in IM Therapeutics.
-
Who are IM Therapeutics’s competitors?
Second Genome, Allogene Therapeutics, AnTolRx, NexImmune, and Xenikos are some of the 55 competitors of IM Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
